Drug intelligence / Profile preview

RenuTend

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

RenuTend is a veterinary stem cell therapy developed by Boehringer Ingelheim for the treatment of tendon and suspensory ligament injuries in horses. The active ingredient consists of tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells. Administered via intralesional injection, RenuTend improves the quality of tendon healing by promoting the parallel alignment of tendon fibers and reducing the formation of scar tissue. It was approved by the European Medicines Agency in 2022, becoming the first licensed product for this indication in the equine market.

Brand names: RenuTend
Other names: tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells

Beyond the preview

Go deeper on RenuTend.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenuTend.

Explore the full profile